Breaking News: BLACKCAPS v Australia Day/Night Test

Having trouble viewing this email? Click here

Member: MBC3970144

BREAKING NEWS: Day/night Test to celebrate closer trans-Tasman ties

Cricket's first day/night Test will form the cornerstone of a newly-enhanced relationship between New Zealand Cricket and Cricket Australia.

To be played in Adelaide from November 26 to 30, the unique and historic clash - part of a 3 Test series carrying a total prize pool of $1m, will usher in a new era of trans-Tasman rivalry, including a total of 10 Tests and 8 Chappell Hadlee series over the next 7 years.

The BLACKCAPS and Australia, who played in front of the biggest official crowd ever recorded during the ICC Cricket World Cup final, will meet in a total of 28 ODIs in that 7 year period.

Read full story

You have received this e-mail as you have opted in to receiving news and offers from New Zealand Cricket. If you no longer wish to receive our emails, click the link below:
Unsubscribe

New Zealand Cricket Level 3, 8 Nugent Street Grafton, Auckland 1023 New Zealand (649) 972-0605

Comments

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition. In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates. So, why is this approval so important? First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com . Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday. It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly? The answer isn't clear yet. We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct. But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side

DBTECH

Search This Blog